AUPH logo

Aurinia Pharmaceuticals Inc. Stock Price

NasdaqGM:AUPH Community·US$2.1b Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AUPH Share Price Performance

US$16.25
4.03 (32.98%)
​
US$18.17
Fair Value
US$16.25
4.03 (32.98%)
10.6% undervalued intrinsic discount
US$18.17
Fair Value
Price US$16.25
AnalystConsensusTarget US$18.17
Simplicity_Over_Noise US$21.00
AnalystLowTarget US$16.00

AUPH Community Narratives

Fair Value
·
Fair Value US$18.17 10.6% undervalued intrinsic discount

AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments

0users have liked this narrative
1users have commented on this narrative
16users have followed this narrative
Fair Value
·
Fair Value US$21 22.6% undervalued intrinsic discount

Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Fair Value
·
Fair Value US$16 1.6% overvalued intrinsic discount

Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AUPH logo
Aurinia Pharmaceuticals
22.6% undervalued intrinsic discount

Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche

View narrative
Updated 17 Jul
Read Narrative
AUPH logo
Aurinia Pharmaceuticals
10.6% undervalued intrinsic discount

AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments

View narrative
Updated 21 Aug
Read Narrative
AUPH logo
Aurinia Pharmaceuticals
1.6% overvalued intrinsic discount
Updated

Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook

View narrative
Updated 4 Sep
Read Narrative
AUPH logo
Aurinia Pharmaceuticals
22.1% undervalued intrinsic discount

Aging Demographics And LUPKYNIS Uptake Will Expand Markets

View narrative
Updated 24 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Updated Narratives

AUPH logo

Aritinercept Advances, but Commercialization Remains a 2030s Story

Fair Value: US$21 22.6% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AUPH logo

AUPH: Future Returns Will Hinge On Patent Protection And Execution

Fair Value: US$16 1.6% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AUPH logo

AUPH: Patent Win And Clinical Progress Will Support A Balanced 2026 Outlook

Fair Value: US$18.17 10.6% undervalued intrinsic discount
16 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

3 Risks
3 Rewards
View Full Analysis

Aurinia Pharmaceuticals Inc. Key Details

US$311.5m

Revenue

US$68.9m

Cost of Revenue

US$242.6m

Gross Profit

-US$71.5m

Other Expenses

US$314.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.36
77.88%
100.84%
0%
View Full Analysis

About AUPH

Founded
1993
Employees
128
CEO
Kevin Tang
WebsiteView website
www.auriniapharma.com

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Recent AUPH News & Updates

Narrative Update • Sep 04

AUPH: Future Returns Will Hinge On Patent Protection And Execution

Analysts have raised their price target on Aurinia Pharmaceuticals from $15.00 to $16.00, citing updated assumptions related to discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Aurinia Pharmaceuticals Aurinia Pharmaceuticals and Teva Pharmaceutical Industries reached a settlement on patent litigation related to Teva’s planned generic voclosporin capsules.

Recent updates

No updates

Aurinia Pharmaceuticals Inc. Competitors

BMRN logo

BioMarin Pharmaceutical

Symbol: NasdaqGS:BMRN
Market cap: US$12.5b
MDGL logo

Madrigal Pharmaceuticals

Symbol: NasdaqGS:MDGL
Market cap: US$12.3b
CORT logo

Corcept Therapeutics

Symbol: NasdaqCM:CORT
Market cap: US$12.3b
HALO logo

Halozyme Therapeutics

Symbol: NasdaqGS:HALO
Market cap: US$12.3b
View more competitors